Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2010. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific transaction within a retirement plan rather than general corporate financial performance.
Material Changes
Following a re-valuation of the cash element of the notional investment held within the US Retirement Savings Plan (notionally held in GSK Ordinary share ADRs), an increase in the notional allocation of Ordinary share ADRs occurred on February 11, 2010. The transaction price was $38.47 per ADR.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It is a compliance notification under Disclosure and Transparency Rule 3.1.4R(1)(a).
Important Facts for Investors
- Transaction Date: February 11, 2010 (Notification date: February 12, 2010).
- Transaction Price: $38.47 per ADR.
- Participants: Dr M M Slaoui (8 units), Mrs C Bruck Slaoui (2 units), Mr E J Gray (25 units), Mr W C Louv (15 units), and Dr D Pulman (29 units).
- Nature of Event: Increase in notional allocation of Ordinary share ADRs within the US Retirement Savings Plan.